Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Eledon Pharmaceuticals will present new clinical data for its lead asset tegoprubart at the American Transplant Congress in Boston from June 20-24, 2026. The company will deliver an oral presentation on June 22 regarding the Phase 2 BESTOW trial, focusing on safety and efficacy in preventing kidney transplant rejection. A poster presentation on June 20 will cover long-term data from the Phase 2 BESTOW extension study. A conference call to discuss the results is scheduled for June 22 at 8:00 a.m.
Key figures
- Drug Name
- tegoprubart
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.